Catalyst Pharmaceutical Partners Inc. (CPRX) Stock Research, Analysis & News

Quick Analysis on Catalyst Pharmaceutical Partners Inc. (CPRX) Stock as of October 21, 2017

Previous Closing Price $2.62 is above 50 day moving average of $2.56
Previous Closing Price $2.62 is above 200 day moving average of $2.44
The Stock pays no dividend
The closing price $2.62 is more than 107.63% away from its one year target price of $5.44
Current Short Ratio 5.67 is great than 1
Next year EPS Estimate of $-0.25 is lower than curreny year EPS Estimate $-0.23
Earning per Share $-0.20 is negative. Catalyst Pharmaceutical Partners Inc. is lossing money.
EBITDA $-16.44M is negative
It is a very small cap stock with market cap of $233.37M
(See more information about Catalyst Pharmaceutical Partners Inc. (CPRX) Stock below)

Catalyst Pharmaceutical Partners Inc. (CPRX) Stock Profile Summary

Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including epilepsy and drug addiction. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceutical Partners Inc. (CPRX) Stock Key Statistics Research and Analysis as of October 21, 2017

Stock ExchangeNCM
Market Capitalization$233.37M
Trade Volume (Average Trading Volume)758,118 (569,288)
Price/Book6.52
Earning/Share$-0.20
Current Year EPS Estimate$-0.23
Next Year EPS Estimate$-0.25
Previous Closing Price$2.62
50 Day Price Moving Average$2.56
200 Day Price Moving Average$2.44
1 yr Target Price$5.44
PEG Ratio0.00
Short Ratio5.67
EBITDA$-16.44M

Catalyst Pharmaceutical Partners Inc. (CPRX) Stock Competitor Research and Analysis

Sanofi-Aventis (SNY)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Stock Research on Catalyst Pharmaceutical Partners Inc. (CPRX)

Latest Market News on Catalyst Pharmaceutical Partners Inc. (CPRX)


Click here to find the latest news on Catalyst Pharmaceutical Partners Inc. (CPRX)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Sanofi-Aventis (SNY)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)